BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Codexis, Inc. (MAXY) To Acquire Julich Fine Chemicals, Leading European Biocatalyst And Pharmaceutical Intermediate Provider


10/19/2005 5:12:47 PM

REDWOOD CITY, Calif., Feb. 22 /PRNewswire/ -- Codexis, Inc., a privately held biosciences company, today announced it has acquired Germany's Julich Fine Chemicals GmbH (JFC), a leading supplier of specialty enzymes (biocatalysts) for organic synthesis and chiral building blocks to pharmaceutical and chemical companies worldwide. The acquisition is expected to make a positive cash contribution to Codexis in its first full year of operations. Additional financial terms were not disclosed.

JFC is one of Europe's leading providers of products and services for the biocatalytic production of chiral pharmaceutical intermediates. JFC will operate as an independent, wholly owned subsidiary of Codexis. Through its catalog, http://www.juelich-chemicals.de/shop.html , JFC offers a wide range of off-the-shelf specialty enzymes and chiral intermediates useful in pharmaceutical development. JFC will be an outlet for several of Codexis' proprietary enzymes, while Codexis will continue to focus on using its MolecularBreeding(TM) directed molecular evolution technology to provide proprietary, customized solutions directly to leading pharmaceutical companies worldwide.

"The acquisition of JFC is part of our strategic expansion into international markets, in particular Europe. We believe it will accelerate adoption of Codexis' biocatalytic approach to pharmaceutical process research and manufacturing, an area historically dominated by synthetic organic chemistry," said Alan Shaw, Ph.D., President and Chief Executive Officer of Codexis.

"Synergies between our companies can lead to accelerated revenue growth and greater market presence in Europe," Dr. Shaw added. "Codexis will continue to leverage its MolecularBreeding(TM) technology platform, streamlining Phase I and Phase II drug development and creating valuable intellectual property for our pharmaceutical partners."

"Our companies bring complementary expertise and market knowledge to the complex manufacturing challenges facing today's pharmaceutical companies," said Thomas Daussmann, Ph.D., Managing Director of JFC, who will join the Codexis leadership team. "We look forward to being part of Codexis as we address this rapidly growing worldwide market."

About the Company

Codexis is a privately held biosciences company applying proprietary protein and strain engineering technologies to create novel process development solutions for efficient, cost-effective and environmentally friendly pharmaceutical manufacturing. Application of the Codexis technology can also generate new intellectual property opportunities for pharmaceutical manufacturers, which may extend a product lifecycle. The company has more than 10 strategic alliances, including a major agreement with Pfizer, and more than 15 products and processes in development internally and at leading worldwide life sciences companies. Codexis, Inc. began operations as an independent company in 2002.

For more information about Codexis and its applications, please visit http://www.codexis.com/. Codexis is a trademark of Codexis, Inc.

Julich Fine Chemicals GmbH, a Codexis company, is focused on the production of chiral fine chemicals using biological systems such as isolated enzymes and microorganisms. Founded in 1999 as a spin-off from the Research Centre Julich in Germany, JFC offers specialty enzymes for organic chemistry, chiral intermediates and R&D services in biocatalysis. Specialty enzymes, including oxidoreductases, transferases, hydrolases (lipases, esterases, nitrilases) and lyases (oxynitrilases), are available for sale via JFC's catalog. The company also applies these enzymes for the production of chiral intermediates, including optically active alcohols, diols, hydroxy esters and amines. JFC's in-house production capabilities range from a few grams to the 100-kg scale, while quantities at the multi-ton scale are available through JFC's established manufacturing partners.

To learn more about JFC, including access to its catalog of products, please visit http://www.juelich-chemicals.com/ .

Contact: Codexis, Inc. Tassos Gianakakos Sr. Vice President, Business Development T. 650-298-5423 F. 650-298-5449 tassos.gianakakos@codexis.com Media: Kathy L. Nugent, Ph.D. Burns McClellan 212-213-0006 knugent@burnsmc.com

Codexis, Inc.

CONTACT: Tassos Gianakakos, Sr. Vice President, Business Development ofCodexis, Inc., +1-650-298-5423, or fax, +1-650-298-5449, ortassos.gianakakos@codexis.com; or Kathy L. Nugent, Ph.D. of Burns McClellan,+1-212-213-0006, or knugent@burnsmc.com, for Codexis, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES